The drug has grabbed attention as one of the most promising treatments for Covid-19
Beximco Pharmaceuticals has said it has submitted final product samples of its Remdesivir to the drug administration on May 7.
In a statement sent to the media on Saturday, the drug manufacturer referred to reports ran by several outlets on Friday which said that Eskayef Pharmaceuticals was the first Bangladeshi company to produce the drug used to treat coronavirus patients.
“We would like to clarify that Beximco Pharma not only was the first company in Bangladesh to produce this drug but also the only company which has submitted final product samples to drug regulatory authority, Directorate General of Drug Administration (DGDA), for testing and approval. After producing this generic drug and successfully conducting all necessary tests in house, we submitted final product samples to DGDA on 7th May 2020 for testing and approval,” it reads.
The DGDA said that Eskayef submitted samples of its Remdesivir on Saturday.
“Beximco sent their samples on Wednesday and Eskayef today, though they were supposed to submit it yesterday,” said Ruhul Amin, a director with the DGDA.
Tests and chemical analysis of Beximco’s sample have already begun, he said before adding, “The analysis on Eskayef samples may start today or tomorrow.”
In its statement, Beximco said they had decided not to make an announcement over Remdesivir before getting the drug administration’s nod.
“Beximco Pharma refrained from announcing that it has produced the drug because it felt doing so without being validated by the regulatory body would have been irresponsible and unethical and would have mislead the public,” the company said in the statement.
Apart from Beximco and Eksayef, four other Bangladeshi drug manufacturers received the DGDA’s approval to produced Remdesivir.
They are, Beacon Pharmaceuticals, Incepta Pharmaceuticals, Health Care Pharmaceuticals and Square Pharmaceuticals.
Remdesivir, a drug developed by Gilead Sciences in the US, has grabbed attention as one of the most promising treatments for Covid-19, the respiratory disease caused by the novel coronavirus that has killed more than 250,000 people